Business · 10/06/2015Updated: 10/17/2026 · 1 min read
Baxter Healthcare Corporation et al. Withdraw FDA Approval for Ondansetron Injection and ANDAs
Summary
The FDA is withdrawing approval for a new drug application and four Abbreviated New Drug Applications for Ondansetron, following voluntary requests from the applicants to waive a hearing.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →